Recent Updates
Recently added Catalysts

5% Tavilermide

Phase 3

Dry Eye Syndromes | Small molecule | Ophthalmology |BrainsWay Ltd.|Last Updated: Jun 10, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment642

FDA Designations

No designations recorded

Clinical trial landscape

5% Tavilermide · 1 trial · 3 indications

Phase 3 1
NCT05848128Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry EyeDry Eye Syndromes
COMPLETED642 Analytics
PHASE3COMPLETED
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Dry Eye SyndromesUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline in Total Corneal Fluorescein Staining as Measured by the NEI Scale
Baseline to Day 85

The National Eye Institute (NEI) scale is a standardized grading system of 0-3 was used for each of the 5 areas on each cornea (central, superior, temporal, nasal, and inferior). Grade 0 was specified when no staining is present. The maximum score was 15.

Change From Baseline in Eye Dryness Score as Measured by the VAS
Baseline to Day 85

The Visual Analog Scale (VAS) where subjects were asked to rate their eye dryness (OU) by placing a vertical mark on the horizontal line to indicate their current level of discomfort. 0 mm corresponds to "No Discomfort," and 100 mm corresponds to "Maximal Discomfort." The length of the assessment line is 100 mm.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
5% Tavilermide ophthalmic solutionEXPERIMENTAL -
Vehicle ophthalmic solutionPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
5% Tavilermide ophthalmic solutionDRUGTwice a day topicial dosing
Vehicle ophthalmic solutionOTHERTwice a day topical dosing
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites29

Inclusion Criteria: * Subject-reported history of dry eye disease in both eyes for at least 6 months; * History of use of artificial tear eye drops for dry eye symptoms; * Total score of ≥40 on SANDE; * TFBUT; * Corneal fluorescein staining; * Lissamine green conjunctival staining; * Schirmer's tes...

Countries:United States
Unlock Eligibility Criteria